Immunosuppressive and immunomodulatory agents | Total number of patients n (%) | Autoimmune diseases with chronic immunomodulatory therapy n (%) | Hematological malignancies n (%) | Solid tumors, Organ transplants n (%) | Sarcoidosis n (%) | Mixed connective tissue disease n (%) |
---|---|---|---|---|---|---|
Natalizumab | 5/37 (13,5) | 5/6 (83) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Allogenic stem cell transplantation | 2/37 (5) | 0 (0) | 2/6 (33) | 0 (0) | 0 (0) | 0 (0) |
Other immunosuppressive agents | ||||||
Combination chemotherapy* | 5/37 (13,5) | 0 (0) | 5/6 (83) | 1/2 (50) | 0 (0) | 0 (0) |
Prednisolon only | 1/37 (3) | 0 (0) | 0 (0) | 0 (0) | 1/5 (3) | 0 (0) |
Tacrolimus | 1/37 (3) | 0 (0) | 0 (0) | 1/2 (50) | 0 (0) | 0 (0) |
Azathioprine | 3/37 (8) | 1/6 (17) | 0 (0) | 0 (0) | 1/5 (3) | 1/1 (100) |
Methotrexate | 1/37 (3) | 0 (0) | 0 (0) | 0 (0) | 1/5 (3) | 0 (0) |
HIV/ AIDS, Human immunodeficiency virus/ Acquired Immune Deficiency Syndrome.
PSC, primary sclerosing cholangitis; AIH, autoimmune Hepatitis.
One patient was diagnosed with both, a solid tumor and a hematological malignancy.